LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) released its earnings results on Monday. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.25), Zacks reports.
LogicBio Therapeutics Stock Performance
Shares of OTCMKTS:LOGC opened at $15.15 on Monday. The company has a 50 day moving average price of $14.76 and a 200 day moving average price of $10.34. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The stock has a market capitalization of $692.82 million, a price-to-earnings ratio of -20.75 and a beta of 2.11. LogicBio Therapeutics has a 1-year low of $7.05 and a 1-year high of $15.60.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
Read More
- Five stocks we like better than LogicBio Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
